NLS Pharmaceutics Ltd
ZURICH, Zurich, Switzerland · Biotechnology, Healthcare, Health Care
NLS Pharmaceutics is a biopharmaceutical company that specializes in developing innovative therapies for patients with central nervous system disorders. The company's focus includes a diversified pipeline aimed at addressing serious unmet medical needs. It aims to improve the lives of patients through advanced drug delivery systems and small-molecule expertise.
Key facts
- Headquarters
- ZURICH, Zurich, Switzerland
- Employees
- 30
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (NCEL)
- Website
- nlspharma.com
- Company page
Recent activity at NLS Pharmaceutics Ltd
- : NLS Pharmaceutics Ltd
- : NLS Pharmaceutics Ltd
- : NLS Pharmaceutics Ltd
- : NLS Pharmaceutics Ltd
- : NLS Pharmaceutics Launches Preclinical Program for Mazindol ER to Treat Fentanyl Dependence
- : NLS Pharmaceutics Ltd
- : NLS Pharmaceutics and Kadimastem Announce Initial Closing of $500,000 Fundraising Effort for Merger
- : NLS Pharmaceutics Ltd
- : NLS Pharmaceutics Ltd
- : NLS Pharmaceutics Ltd
NLS Pharmaceutics Ltd funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Venture | $2.9M |
| May 2026 | Venture | $3.4M |
| Jul 2025 | Seed | $1.0M |
| Apr 2025 | Seed | $2.0M |
| Jan 2025 | Seed | $500K |
Leadership
- Ronen Twito, Executive Chairman & CEO
- Alex Zwyer, Executive Officer, Director
- Gian-Marco Rinaldi de la Cruz, Director
- Stig Lokke Pedersen, Director
- Myoung-Ok Kwon, Director
- Ronald Hafner, Director
- Chad Hellmann, Executive Officer
- Alexander Zwyer, Executive Officer
- Eric Konofal, Chief Scientific Officer
Verified email and direct lines for NLS Pharmaceutics Ltd’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
NLS Pharmaceutics Ltd in the news
- NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem - PR Newswire (Oct 29, 2025)
- NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares - PR Newswire (Oct 29, 2025)
- NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform - Finansavisen (Feb 27, 2025)
- NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models - Finansavisen (Apr 15, 2025)
- NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs - PR Newswire (Oct 30, 2025)
- NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy - PR Newswire (Jul 17, 2025)
- NLS Pharmaceutics Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex® (Mazindol) - PR Newswire (Mar 12, 2021)
- NLS Pharmaceutics to Present at The MicroCap Rodeo 2021 Summer Solstice: Best Ideas from the Buyside Conference on June 1 - PR Newswire (May 28, 2021)
Companies similar to NLS Pharmaceutics Ltd
- Century Therapeutics · Biotechnology, Healthcare, Health Care, Manufacturing, Therapeutics
- Gyre Therapeutics · Biotechnology, Healthcare, Health Care, Manufacturing, Therapeutics
- AbbVie Inc. · Biotechnology, Healthcare, Health Care, Manufacturing, Therapeutics
- CurvaFix · Biotechnology, Healthcare, Health Care, Manufacturing
- AIM ImmunoTech · Biotechnology, Healthcare, Health Care, Therapeutics
About NLS Pharmaceutics Ltd: questions and answers
What does NLS Pharmaceutics Ltd do?
NLS Pharmaceutics is a biopharmaceutical company that specializes in developing innovative therapies for patients with central nervous system disorders. The company's focus includes a diversified pipeline aimed at addressing serious unmet medical needs. It aims to improve the lives of patients through advanced drug delivery systems and small-molecule expertise.
Where is NLS Pharmaceutics Ltd headquartered?
NLS Pharmaceutics Ltd is headquartered in ZURICH, Zurich, Switzerland.
How many employees does NLS Pharmaceutics Ltd have?
NLS Pharmaceutics Ltd has about 30 employees.
Has NLS Pharmaceutics Ltd raised funding?
Yes. Fundz has recorded 5 funding events for NLS Pharmaceutics Ltd. The most recent, $2.9M, was in Aug 2026.
Who leads NLS Pharmaceutics Ltd?
Ronen Twito is an Executive Chairman & CEO at NLS Pharmaceutics Ltd.
What is the latest news on NLS Pharmaceutics Ltd?
On Aug 24, 2026, NLS Pharmaceutics Ltd
Is NLS Pharmaceutics Ltd a public company?
Yes. NLS Pharmaceutics Ltd is publicly traded under the ticker NCEL.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy